Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
PRGO 
Perrigo Company PLC (PRGO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/03/2025: PRGO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $21.5
1 Year Target Price $21.5
| 1 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -54.42% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.92B USD | Price to earnings Ratio - | 1Y Target Price 21.5 |
Price to earnings Ratio - | 1Y Target Price 21.5 | ||
Volume (30-day avg) 5 | Beta 0.36 | 52 Weeks Range 11.91 - 29.27 | Updated Date 12/4/2025 |
52 Weeks Range 11.91 - 29.27 | Updated Date 12/4/2025 | ||
Dividends yield (FY) 8.55% | Basic EPS (TTM) -0.21 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-05 | When - | Estimate 0.76 | Actual 0.8 |
Profitability
Profit Margin -1.21% | Operating Margin (TTM) 8.97% |
Management Effectiveness
Return on Assets (TTM) 2.92% | Return on Equity (TTM) -0.65% |
Valuation
Trailing PE - | Forward PE 4.76 | Enterprise Value 5118692524 | Price to Sales(TTM) 0.45 |
Enterprise Value 5118692524 | Price to Sales(TTM) 0.45 | ||
Enterprise Value to Revenue 1.2 | Enterprise Value to EBITDA 8.56 | Shares Outstanding 137624009 | Shares Floating 136796889 |
Shares Outstanding 137624009 | Shares Floating 136796889 | ||
Percent Insiders 0.41 | Percent Institutions 112.03 |
Upturn AI SWOT
Perrigo Company PLC
Company Overview
History and Background
Perrigo Company PLC was founded in 1887 in Allegan, Michigan, as a packaging company. Over time, it transitioned to manufacturing over-the-counter (OTC) pharmaceuticals and nutritional products, becoming a leading private-label supplier.
Core Business Areas
- Consumer Self-Care Americas (CSCA): Focuses on the development, manufacturing, and marketing of OTC products, store brand healthcare, and infant formula in the Americas.
- Consumer Self-Care International (CSCI): Focuses on the development, manufacturing, and marketing of OTC products and store brand healthcare outside of the Americas.
Leadership and Structure
Perrigo is led by a Board of Directors and a senior management team. The company operates globally with headquarters in Dublin, Ireland.
Top Products and Market Share
Key Offerings
- Infant Formula: Perrigo is a major supplier of store-brand infant formula. They face competition from Abbott (ABT), Nestle (NSRGY), and Reckitt Benckiser (RBGLY). Market share data is difficult to pinpoint exactly due to the private label nature, but Perrigo holds a significant portion of the private label market.
- Allergy Relief Products: Perrigo manufactures and distributes a wide variety of allergy medications including cetirizine, loratadine and fexofenadine store brand versions competing with brands like Benadryl (JNJ), Zyrtec (JNJ) and Allegra (SNY).
- Cough, Cold, and Flu Medications: Perrigo manufactures OTC cough, cold and flu medicines. Key competitors include Procter & Gamble (PG), Johnson & Johnson (JNJ) and Reckitt Benckiser (RBGLY).
Market Dynamics
Industry Overview
The OTC pharmaceutical industry is characterized by steady growth driven by an aging population, increasing healthcare costs, and a shift towards self-medication. The industry is also impacted by regulatory changes and consumer preferences for natural and organic products.
Positioning
Perrigo is a leading provider of store-brand OTC products, offering consumers affordable alternatives to branded medications. The company's competitive advantage lies in its manufacturing capabilities, extensive distribution network, and focus on private label development.
Total Addressable Market (TAM)
The global OTC market is estimated at over $150 billion. Perrigo's positioning in the store-brand segment allows it to capture a significant share of this market by offering more affordable options, appealing to cost-conscious consumers.
Upturn SWOT Analysis
Strengths
- Strong market position in private-label OTC products
- Extensive manufacturing and distribution network
- Focus on cost-effective product development
- Diversified product portfolio
Weaknesses
- Dependence on retail partners for distribution
- Exposure to price competition from other private-label manufacturers
- Potential for product liability claims
- Vulnerability to changes in consumer preferences
Opportunities
- Expanding into new geographic markets
- Developing innovative OTC products and formulations
- Acquiring smaller OTC brands or companies
- Increasing penetration in e-commerce channels
Threats
- Increased competition from branded pharmaceutical companies
- Regulatory changes impacting OTC drug approvals
- Economic downturns affecting consumer spending
- Supply chain disruptions
Competitors and Market Share
Key Competitors
- JNJ
- PG
- RBGLY
- ABT
- SNY
Competitive Landscape
Perrigo competes primarily on price and private-label expertise. Its advantages include established relationships with retailers. Disadvantages include lower brand recognition compared to large pharma companies.
Major Acquisitions
HRA Pharma
- Year: 2022
- Acquisition Price (USD millions): 2100
- Strategic Rationale: Expanded Perrigo's presence in self-care products, including women's health, and strengthens European market position.
Growth Trajectory and Initiatives
Historical Growth: Perrigo has experienced both organic and inorganic growth through acquisitions. Historical growth rates vary based on economic conditions and industry trends.
Future Projections: Future growth projections are based on analyst estimates which are based on market conditions, competitors, and product roadmap.
Recent Initiatives: Recent initiatives include focusing on core OTC segments, streamlining operations, and investing in innovation.
Summary
Perrigo is a strong player in the OTC private label market, leveraging its manufacturing capabilities and retail partnerships. While its lack of branded products poses a challenge, focusing on innovation and market expansion presents growth opportunities. They need to be aware of their competitors in order to continue to have competitive advantages.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Perrigo Company PLC Investor Relations
- SEC Filings
- Industry Reports
- Market Research Reports
- Analyst Estimates
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a financial advisor. Market Share data are estimates.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Perrigo Company PLC
Exchange NYSE | Headquaters - | ||
IPO Launch date 1991-12-16 | President, CEO & Director Mr. Patrick Lockwood-Taylor | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 8379 | Website https://www.perrigo.com |
Full time employees 8379 | Website https://www.perrigo.com | ||
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.